Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003167 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Advanced Bladder Cancer
A Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00003167 is a Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 102-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00003167, a Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
Conditions Studied
Interventions
- BIOLOGICAL Ad5CMV-p53 gene
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1998-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003167
The ClinicalTrials.gov registry entry for NCT00003167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (76% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ad5CMV-p53 gene is the first listed.
NCT00003167 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00003167 about?
NCT00003167 is a clinical study titled "Gene Therapy in Treating Patients With Advanced Bladder Cancer". Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
What is the current status of trial NCT00003167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1998-05.
What conditions does trial NCT00003167 study?
This clinical trial studies the following conditions: Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Stage III Bladder Cancer, Stage I Bladder Cancer.
What interventions are being tested in trial NCT00003167?
The interventions under investigation include: Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003167?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003167 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
RECRUITING
-
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
COMPLETED · Phase 2
-
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Bladder Cancer
All registered trials for this condition
Transitional Cell Carcinoma of the Bladder
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.